Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|December 15, 2004
New VP oversees pegaptanib development
New York-Eyetech Pharmaceuticals has appointed Barrett Katz, MD, as its vice president of medical strategy.
Advertisement
New York-Eyetech Pharmaceuticals has appointed Barrett Katz, MD, as its vice president of medical strategy.
Dr. Katz, who was most recently chairman of the department of ophthalmology at George Washington University School of Medicine and a professor of ophthalmology, neurology, and neurosurgery there, will help guide the phase IIIb/IV clinical protocols and trials for pegaptanib sodium injection (Macugen).
The drug, which is under FDA review for the treatment of wet age-related macular degeneration, is being developed with Pfizer Ophthalmics. Dr. Katz will serve as senior liaison to the new Pfizer Inc. division.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
2
Practical ways to extend anti-VEGF control in RVO, AMD, and DME
3
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
4
Comments from the FDA Advisory Committee meeting on SYD-101
5